{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Fostriecin",
  "nciThesaurus": {
    "casRegistry": "87810-56-8",
    "chebiId": "",
    "chemicalFormula": "C19H27O9P",
    "definition": "An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types.  This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation.",
    "fdaUniiCode": "ZO1648L551",
    "identifier": "C1372",
    "preferredName": "Fostriecin",
    "semanticType": "Antibiotic",
    "subclassOf": [
      "C1968",
      "C2159"
    ],
    "synonyms": [
      "2H-pyran-2-one,5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11,-tridecatetraenyl)-,trans",
      "FOSTRIECIN",
      "FST",
      "Fostriecin",
      "Phosphotrienin"
    ]
  }
}